Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS).
Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. Chida K, et al. Among authors: enomoto m. Front Oncol. 2021 Mar 8;11:576036. doi: 10.3389/fonc.2021.576036. eCollection 2021. Front Oncol. 2021. PMID: 33763345 Free PMC article.
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y. Moriwaki T, et al. Among authors: enomoto m. Oncologist. 2018 Jan;23(1):7-15. doi: 10.1634/theoncologist.2017-0275. Epub 2017 Sep 11. Oncologist. 2018. PMID: 28894015 Free PMC article.
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y. Moriwaki T, et al. Among authors: enomoto m. Int J Clin Oncol. 2020 Apr;25(4):614-621. doi: 10.1007/s10147-019-01600-0. Epub 2019 Dec 14. Int J Clin Oncol. 2020. PMID: 31838590
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K, Oki E, Enomoto M, Ihara K, Ando K, Fujita F, Tominaga M, Mori S, Nakayama G, Shimokawa M, Saeki H, Baba H, Mori M, Akagi Y. Miwa K, et al. Among authors: enomoto m. BMC Cancer. 2021 Jan 5;21(1):23. doi: 10.1186/s12885-020-07766-5. BMC Cancer. 2021. PMID: 33402130 Free PMC article. Clinical Trial.
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment.
Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Nakajima H, et al. Among authors: enomoto m. Front Oncol. 2021 Jun 15;11:688709. doi: 10.3389/fonc.2021.688709. eCollection 2021. Front Oncol. 2021. PMID: 34211856 Free PMC article.
Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
Ishiyama S, Yamada T, Nakamura M, Enomoto M, Sugimoto K, Yokomizo H, Kosugi C, Ohta R, Ishimaru K, Sonoda H, Ishibashi K, Kuramochi H, Yoshida Y, Ichikawa D, Hirata K, Yoshida H, Hashiguchi Y, Ishida H, Koda K, Katsumata K, Sakamoto K. Ishiyama S, et al. Among authors: enomoto m. Int J Clin Oncol. 2022 Aug;27(8):1300-1308. doi: 10.1007/s10147-022-02179-9. Epub 2022 May 30. Int J Clin Oncol. 2022. PMID: 35635652 Clinical Trial.
[Examination of Prognostic Factors for Elderly Colon Cancer].
Sujino H, Mazaki J, Udo R, Okazaki N, Tago T, Kasahara K, Enomoto M, Ishizaki T, Nagakawa Y, Katsumata K, Tsuchida A. Sujino H, et al. Among authors: enomoto m. Gan To Kagaku Ryoho. 2021 Dec;48(13):1715-1717. Gan To Kagaku Ryoho. 2021. PMID: 35046307 Japanese.
1,011 results